• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗增殖剂与移植。

Antiproliferatives and Transplantation.

机构信息

Pennsylvania State University College of Medicine- Hershey Medical Center, Hershey, PA, USA.

出版信息

Handb Exp Pharmacol. 2022;272:39-52. doi: 10.1007/164_2021_556.

DOI:10.1007/164_2021_556
PMID:34697667
Abstract

Antiproliferative agents include Mycophenolic acid and Azathioprine (which is less commonly used unless in certain conditions). They were initially identified for use in autoimmune and cancer research due to their role in disruption of cellular replication. They have now become the cornerstone of antirejection maintenance therapy in solid organ transplant. In this chapter we will describe the major times that lead to discovery, mechanisms of action, side effects, use during pregnancy and the major clinical trials.

摘要

抗增殖剂包括霉酚酸和硫唑嘌呤(除非在某些情况下,否则较少使用)。由于它们在破坏细胞复制中的作用,最初被确定用于自身免疫和癌症研究。现在,它们已成为实体器官移植中抗排斥维持治疗的基石。在本章中,我们将描述导致发现的主要时期、作用机制、副作用、妊娠期间的使用以及主要临床试验。

相似文献

1
Antiproliferatives and Transplantation.抗增殖剂与移植。
Handb Exp Pharmacol. 2022;272:39-52. doi: 10.1007/164_2021_556.
2
Immunosuppressants in Organ Transplantation.器官移植中的免疫抑制剂
Handb Exp Pharmacol. 2020;261:441-469. doi: 10.1007/164_2019_331.
3
Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.肾移植中新型免疫抑制方案的临床疗效与成本效益:一项系统评价与模型研究
Health Technol Assess. 2005 May;9(21):1-179, iii-iv. doi: 10.3310/hta9210.
4
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.霉酚酸酯。其药效学、药代动力学特性及在肾移植中的临床疗效综述。
Drugs. 1996 Feb;51(2):278-98. doi: 10.2165/00003495-199651020-00007.
5
Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis.霉酚酸和实体器官移植受者的癌症风险:系统评价和荟萃分析。
Br J Clin Pharmacol. 2022 Feb;88(2):476-489. doi: 10.1111/bcp.14979. Epub 2021 Jul 29.
6
Mycophenolate mofetil: a unique immunosuppressive agent.霉酚酸酯:一种独特的免疫抑制剂。
Am J Health Syst Pharm. 1997 Feb 1;54(3):285-94. doi: 10.1093/ajhp/54.3.285.
7
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.他克莫司在胰腺移植中的应用:一项多中心分析。他克莫司胰腺移植研究组。
Clin Transplant. 1997 Aug;11(4):299-312.
8
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.霉酚酸酯预防尸体肾移植受者急性排斥反应的研究。美国肾移植霉酚酸酯研究组。
Transplantation. 1995 Aug 15;60(3):225-32. doi: 10.1097/00007890-199508000-00003.
9
[Mycophenolate mofetil, a possible new immunosuppresant].霉酚酸酯,一种可能的新型免疫抑制剂
Ceska Slov Farm. 2002 Sep;51(5):220-5.
10
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.霉酚酸酯与硫唑嘌呤预防肾移植急性排斥反应的随机对照试验(MYSS)
Lancet. 2004;364(9433):503-12. doi: 10.1016/S0140-6736(04)16808-6.

本文引用的文献

1
Clinical trials in heart transplantation: The evolution of evidence in immunosuppression.心脏移植的临床试验:免疫抑制证据的演变
J Heart Lung Transplant. 2017 Dec;36(12):1286-1290. doi: 10.1016/j.healun.2017.10.009. Epub 2017 Oct 20.
2
Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.肺移植后依维莫司对比霉酚酸酯:一项前瞻性、随机、开放标签试验。
Am J Transplant. 2016 Nov;16(11):3171-3180. doi: 10.1111/ajt.13835. Epub 2016 Jun 15.
3
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
新发心脏移植受者中早期停用钙调神经磷酸酶抑制剂并开始使用依维莫司治疗:随机SCHEDULE研究的三年结果
Am J Transplant. 2016 Apr;16(4):1238-47. doi: 10.1111/ajt.13588. Epub 2016 Jan 28.
4
Mycophenolate fetal toxicity and risk evaluation and mitigation strategies.霉酚酸胎儿毒性及其风险评估和缓解策略。
Am J Transplant. 2013 Jun;13(6):1383-9. doi: 10.1111/ajt.12238. Epub 2013 Apr 25.
5
Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.依维莫司对比霉酚酸酯在心脏移植中的应用:一项随机、多中心试验。
Am J Transplant. 2013 May;13(5):1203-16. doi: 10.1111/ajt.12181. Epub 2013 Feb 22.
6
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.硫嘌呤甲基转移酶基因型与硫嘌呤剂量的临床药物遗传学实施联盟指南:2013年更新版
Clin Pharmacol Ther. 2013 Apr;93(4):324-5. doi: 10.1038/clpt.2013.4. Epub 2013 Jan 17.
7
Safety of azathioprine use during pregnancy.妊娠期硫唑嘌呤的安全性。
Can Fam Physician. 2011 Dec;57(12):1401-2.
8
Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes?霉酚酸酯监测:是否有证据表明其能改善治疗结果?
Clin Pharmacol Ther. 2011 Aug;90(2):204-6. doi: 10.1038/clpt.2011.95.
9
Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.从霉酚酸酯转换为肠溶包衣的霉酚酸钠药物或制剂的肾移植受者胃肠道生活质量改善情况:霉酚酸酯和肠溶包衣的霉酚酸钠
Transplantation. 2011 Aug 27;92(4):426-32. doi: 10.1097/TP.0b013e31822527ca.
10
Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum.青霉菌中麦考酚酸生物合成的分子基础。
Appl Environ Microbiol. 2011 May;77(9):3035-43. doi: 10.1128/AEM.03015-10. Epub 2011 Mar 11.